POTENTIAL ADVANTAGE OF REPAGLINIDE MONOTHERAPY IN GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES AND SEVERE RENAL IMPAIRMENT.

Mori, K; Emoto, M; Numaguchi, R; Yamazaki, Y; Urata, H; Motoyama, K; Morioka, T; Shoji, T; Inaba, M

Mori, K; Emoto, M; Numaguchi, R; Yamazaki, Y; Urata, H; Motoyama, K; Morioka, T; Shoji, T; Inaba, M.

Afiliación

Mori K; Osaka City University Graduate School of Medicine, Osaka, Japan.
Emoto M; Osaka City University Graduate School of Medicine, Osaka, Japan.
Numaguchi R; Osaka City University Graduate School of Medicine, Osaka, Japan.
Yamazaki Y; Osaka City University Graduate School of Medicine, Osaka, Japan.
Urata H; Osaka City University Graduate School of Medicine, Osaka, Japan.
Motoyama K; Osaka City University Graduate School of Medicine, Osaka, Japan.
Morioka T; Osaka City University Graduate School of Medicine, Osaka, Japan.
Shoji T; Osaka City University Graduate School of Medicine, Osaka, Japan.
Inaba M; Osaka City University Graduate School of Medicine, Osaka, Japan.

Acta Endocrinol (Buchar) ; 13(2): 133-137, 2017.

Article en En | MEDLINE | ID: mdl-31149163

Palabras clave

diabetic nephropathy; renal impairment; repaglinide; type 2 diabetes

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Acta Endocrinol (Buchar) Año: 2017 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Rumanía

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google